CREPT Polyclonal Antibody, PE-Cy5 Conjugated
Product Specifications
Background
Interacts with phosphorylated C-terminal heptapeptiderepeat domain (CTD) of the largest RNA polymerase II subunitPOLR2A, and participates in dephosphorylation of the CTD.Transcriptional regulator which enhances expression of CCND1.Promotes binding of RNA polymerase II to the CCDN1 promoter and tothe termination region before the poly-A site but decreases itsbinding after the poly-A site. Prevents RNA polymerase II fromreading through the 3' end termination site and may allow it to berecruited back to the promoter through promotion of the formationof a chromatin loop. Also enhances the transcription of a number ofother cell cycle-related genes including CDK2, CDK4, CDK6 andcyclin-E but not CDKN1A, CDKN1B or cyclin-A. Promotes cell proliferation.
Synonyms
C20orf77; Cell cycle related and expression elevated protein in tumor; Chromosome 20 open reading frame 77; CREPT; dJ1057B20.2; DKFZp434P0735; FLJ44520; Hypothetical protein LOC58490; Uncharacterized protein C20orf77; RPR1B_HUMAN.
Host
Rabbit
Cross Reactivity
Mouse
Immunogen
221-320/326
Target
CREPT
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5
Source
KLH conjugated synthetic peptide derived from human CREPT
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/670nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Predicted Cross Reactivity
Human, Rat, Chicken
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
